Tags : CheckMate -227 Part 1a

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in

Tuba Khan July 25, 2019

Shots: The P-III CheckMate -227 Part 1a study involves assessing of Opdivo + Yervoy vs platinum-doublet CT in patients with 1L advanced NSCLC across non-squamous and squamous tumor expressing PD-L1 […]readmore

Tags : CheckMate -227 Part 1a

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CheckMate -227 Part 1a

﻿BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in